Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | XBP1 | P17861 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925334 | 0.94 | MAPK10 (0.50) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL10607692 | 0.94 | PDE4A (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL4954143 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL11357728 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL11359991 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL7749303 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL4105918 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL11364443 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL678855 | 0.79 | HTT (0.49) | MAPK10HTTPDE4AADORA2APDE4B | |
| SCHEMBL2048833 | 0.77 | MAPT (0.47) | MAPK10HTTPDE4AADORA2APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875620-B2 | administering uric acid or lithium urate for treating a microbacterial infection(bacteriocidal or bacteriostatic) caused by staphylococcus aureus and streptococcus pyogenes | PIPER MEDICAL, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-0987009-B1 | Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition | SCHWARZKOPF & HENKEL K K (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20070003590-A1 | Methods of Treating Microbial Infections | PIPER MEDICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-0875241-B1 | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition | HENKEL LION COSMETICS CO LTD (JP) | 2004-12-01 | — | — | EP | disclosed |
| CN-1118276-C | Aqueous cosmetic composition contg. stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition | YAMAHATSU SANGYO KASHA LTD (JP) | 2003-08-20 | — | — | CN | disclosed |
| EP-0987009-A1 | Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition | YAMAHATSU SANGYO KAISHA, LTD. (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-6027719-A | A STABLY-SOLUBILIZED URIC ACID IN AN AQUEOUS COSMETIC COMPOSITION INCLUDING AN ACRYLIC ACID/ALKYL (METH)ACRYLATE COPOLYMER OR A (METH)ACRYLIC ACID/POLYOXYETHYLENE GLYCOL COPOLYMER; PH ADJUSTED TO ALKALINE CONDITIONS; HAIR; SKIN; | YAMAHATSU SANGYO KAISHA, LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| CN-1200264-A | Aqueous cosmetic composition contg. stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition | YAMAHATSU SANGYO KASHA LTD (JP) | 1998-12-02 | — | — | CN | disclosed |
| US-5833969-A | BETAINE DERIVATIVE SURFACTANTS; HAIR DYES | YAMAHATSU SANGYO KAISHA, LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| EP-0875241-A2 | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition | YAMAHATSU SANGYO KAISHA, LTD. (JP) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003590-A1 | Methods of Treating Microbial Infections | XDH, MSR1, FPR3 | MAPK10 3959/4885HTT 4201/4885PDE4A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.